This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
100mg | $1390 | To Be Confirmed |
200mg | $2085 | To Be Confirmed |
500mg | $3510 | To Be Confirmed |
Cat #: V5129 CAS #: 502487-67-4 Purity ≥ 98%
Description: SQ109 (NSC-722041) is an antituberculosis drug which is currently in advanced clinical trials for the treatment of drug-susceptible and drug-resistant tuberculosis, it is a novel, potent and selective inhibitor of the trypomastigote form of the parasite with IC50 for cell killing of 50±8 nM.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 330.55 |
---|---|
Molecular Formula | C22H38N2 |
CAS No. | 502487-67-4 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
SMILES Code | C/C(CC/C=C(C)\C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@H](C2)CC1C3 |
Synonyms | SQ109; SQ-109; SQ 109; NSC722041; NSC 722041; NSC-722041; |
Protocol | In Vitro | SQ109 also inhibits extracellular epimastigotes (IC50, 4.6±1 μM) and the clinically relevant intracellular amastigotes (IC50, ~0.5 to 1 μM), with a selectivity index of ~10 to 20. SQ109 has little effect (EC50, ~80 μM) in a red blood cell hemolysis assay. Besides, SQ109 causes major ultrastructural changes in all three life cycle forms, as observed by light microscopy, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). |
---|---|---|
In Vivo | Oral administration of SQ109 (0.1-25 mg/kg per day) to the mice for 28 days results in dose-dependent reductions of mycobacterial load in both spleen and lung comparable to that of EMB administered at 100 mg/kg per day, but is less potent than isoniazid (INH) at 25 mg/kg per day. Pharmacokinetic profiles of SQ109 in mice following a single administration showed its Cmax as 1038 (intravenous (i.v.)) and 135 ng/mL (p.o.), with an oral Tmax of 0.31 h. The elimination t1/2 of SQ109 is 3.5 (i.v.) and 5.2 h (p.o.). The oral bioavailability is 4%. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 3.0253 mL | 15.1263 mL | 30.2526 mL | 60.5052 mL |
5mM | 0.6051 mL | 3.0253 mL | 6.0505 mL | 12.1010 mL |
10mM | 0.3025 mL | 1.5126 mL | 3.0253 mL | 6.0505 mL |
20mM | 0.1513 mL | 0.7563 mL | 1.5126 mL | 3.0253 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.